Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Consensus Rating of “Moderate Buy” from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $3.70.

Several equities analysts recently commented on the stock. Ascendiant Capital Markets increased their price objective on shares of Lucid Diagnostics from $7.75 to $8.00 and gave the company a “buy” rating in a research note on Monday, October 6th. BTIG Research raised their price target on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a report on Friday, September 5th. Wall Street Zen upgraded shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lucid Diagnostics in a research note on Tuesday, October 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, August 13th.

Insider Activity

In related news, Director Dennis Matheis bought 100,000 shares of the stock in a transaction dated Wednesday, August 20th. The stock was purchased at an average cost of $1.02 per share, with a total value of $102,000.00. Following the completion of the purchase, the director owned 665,443 shares of the company’s stock, valued at $678,751.86. This trade represents a 17.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Lucid Diagnostics

A number of large investors have recently added to or reduced their stakes in LUCD. SG Americas Securities LLC acquired a new position in shares of Lucid Diagnostics during the third quarter valued at about $26,000. Luminus Management LLC boosted its position in Lucid Diagnostics by 14.8% in the 3rd quarter. Luminus Management LLC now owns 912,805 shares of the company’s stock worth $922,000 after purchasing an additional 117,975 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Lucid Diagnostics in the 2nd quarter worth approximately $43,000. Invesco Ltd. purchased a new stake in Lucid Diagnostics in the 2nd quarter worth approximately $41,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Lucid Diagnostics during the 2nd quarter valued at approximately $97,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Trading Down 1.6%

Shares of Lucid Diagnostics stock opened at $1.25 on Friday. The company has a 50 day moving average of $1.16 and a 200-day moving average of $1.18. Lucid Diagnostics has a 1-year low of $0.75 and a 1-year high of $1.80. The company has a market cap of $166.85 million, a PE ratio of -1.05 and a beta of 1.19.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.